QQ客服 官方微博 反馈留言

浏览/检索结果: 共8条，第1-8条 帮助 限定条件 专题：中国医学科学院 北京协和医学院    第一署名单位    第一作者单位    通讯作者单位     已选(0)清除 条数/页：5101520253035404550556065707580859095100   排序方式：请选择作者升序作者降序题名升序题名降序发表日期升序发表日期降序提交时间升序提交时间降序 A multicenter RCT of noninvasive ventilation in pneumonia-induced early mild acute respiratory distress syndrome 期刊论文 2019, 卷号: 23, 期号: 1, 页码: 300 作者:  He Hangyong;  Sun Bing;  Liang Lirong;  Li Yanming;  Wang He 收藏  |  浏览/下载：38/0  |  提交时间：2020/01/03 Acute respiratory distress syndrome (ARDS)  Noninvasive ventilation (NIV)  Pneumonia   Molecular characterization of clinical responses to PD-1/PD-L1 inhibitors in non-small cell lung cancer: Predictive value of multidimensional immunomarker detection for the efficacy of PD-1 inhibitors in Chinese patients 期刊论文 2019, 卷号: 10, 期号: 5, 页码: 1303-1309 作者:  Song, Peng;  Cui, Xiaoxia;  Bai, Li;  Zhou, Xiangdong;  Zhu, Xiaoli 收藏  |  浏览/下载：17/0  |  提交时间：2020/01/03 Multi-omics  NSCLC  PD-1  PD-L1 inhibitor  predictive biomarker   Management of anlotinib-related adverse events in patients with advanced non-small cell lung cancer: Experiences in ALTER-0303 期刊论文 2019, 卷号: 10, 期号: 3, 页码: 551-556 作者:  Si, Xiaoyan;  Zhang, Li;  Wang, Hanping;  Zhang, Xiaotong;  Wang, Mengzhao 收藏  |  浏览/下载：13/0  |  提交时间：2020/01/03 Adverse event  anlotinib  multi-target tyrosine kinase inhibitor  non-small cell lung cancer   Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non-Small Cell Lung Cancer The ALTER 0303 Phase 3 Randomized Clinical Trial 期刊论文 2018, 卷号: 4, 期号: 11, 页码: 1569-1575 作者:  Han, Baohui;  Li, Kai;  Wang, Qiming;  Zhang, Li;  Shi, Jianhua 收藏  |  浏览/下载：5/0  |  提交时间：2020/01/03 Quality of life results from a randomized, double-blinded, placebo-controlled, multi-center phase III trial of anlotinib in patients with advanced non-small cell lung cancer 期刊论文 2018, 卷号: 122, 页码: 32-37 作者:  Si, Xiaoyan;  Zhang, Li;  Wang, Hanping;  Zhang, Xiaotong;  Wang, Mengzhao 收藏  |  浏览/下载：7/0  |  提交时间：2020/01/03 Anlotinib  Non-small cell lung cancer  Quality of life   Prognostic factors of refractory NSCLC patients receiving anlotinib hydrochloride as the third- or further-line treatment 期刊论文 2018, 卷号: 15, 期号: 4, 页码: 443-451 作者:  Wang, Jing;  Zhao, Yizhuo;  Wang, Qiming;  Zhang, Li;  Shi, Jianhua 收藏  |  浏览/下载：2/0  |  提交时间：2020/01/03 Non-small cell lung cancer  anlotinib  prognostic factor analysis  third- or further-line therapy   Efficacy and safety of third-line treatment with anlotinib in patients with refractory advanced non-small-cell lung cancer (ALTER-0303): a randomised, double-blind, placebo-controlled phase 3 study 期刊论文 2017, 卷号: 18, 页码: S3-S3 作者:  Han, Baohui;  Li, Kai;  Wang, Qiming;  Zhao, Yizhuo;  Zhang, Li 收藏  |  浏览/下载：2/0  |  提交时间：2020/01/03 A Randomized Phase III Clinical Trial of Anlotinib Hydrochloride in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) 期刊论文 2017, 卷号: 12, 期号: 1, 页码: S886-S887 作者:  Han, Baohui;  Li, Kai;  Zhao, Yizhuo;  Wang, Qiming;  Zhang, Li 收藏  |  浏览/下载：10/0  |  提交时间：2020/01/03 NSCLC  Anlotinib  multi-targeted tyrosine kinase inhibitor